First-in-human study of a thorium-227-labeled mesothelin-targeting antibody-chelator conjugate (MSLN-TTC), in patients with malignant mesothelioma and other solid tumors.

ABSTRACT:

Introduction

BAY 2287411 [²²⁷Th-anetumab corixetan; mesothelin-targeting antibody-chelator conjugate (MSLN-TTC)] is a targeted alpha therapy consisting of a fully human mesothelin-targeting monoclonal antibody conjugated with a 3,2-hydroxypyridinone (3,2-HOPO) chelator radiolabeled with the alpha particle-emitting radionuclide thorium-227. This phase I study determined the safety, pharmacokinetics, and antitumor activity of MSLN-TTC in mesothelin-expressing mesothelioma and serous ovarian cancer.

Methods

MSLN-TTC was administered i.v. 1.5, 2.5, or 3.5 MBq of thorium-227 and with a total antibody dose of 10, 30, 50, or 150 mg every 6 weeks to 36 patients included in the intention-to-treat population. Adverse events, tumor response according to RECIST 1.1 and mRECIS

SUBMITTER: Minchom A 

PROVIDER: S-EPMC12670091 | biostudies-literature | 2025 Dec

REPOSITORIES: biostudies-literature